Antiviral therapy for recurrent liver graft infection with hepatitis C virus

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Gurusamy, Kurinchi Selvan ^a   Samraj, K ^b   Davidson, B R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ANEMIA; DEPRESSION; GRAFT INFECTION; GRAFT REJECTION; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; KIDNEY FAILURE; LIVER GRAFT; MORTALITY; OUTCOME ASSESSMENT; PROPHYLAXIS; REINFECTION; REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

EID: 44949171687     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006803     Document Type: Review

References (33)

1. Berenguer 2003 Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al.A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38(1):34-41.
2. Bombuy 2004 Bombuy E, Fondevila C, Rodriguez-Laiz G, Ferrer J, Amador A, Valentini M, et al.Ischemic preconditioning in adult living donor liver transplantation, a pilot study [EASL abstract]. Journal of Hepatology 2004;40(Suppl 1):39.
3. Cameron 2006 Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, et al.Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Annals of Surgery 2006;244(4):563-71.
4. Cescon 2006 Cescon M, Grazi GL, Grassi A, Ravaioli M, Vetrone G, Ercolani G, et al.Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study. Liver Transplantation 2006;12(4):628-35.
5. Chalasani 2005 Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al.Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41(2):289-98.
6. Corno 2006 Corno V, Colledan M, Dezza MC, Guizzetti M, Lucianetti A, Maldini G, et al.Extended right split liver graft for primary transplantation in children and adults. Transplantation International 2006;19 (6):492-9.
7. DeMets 1987 DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
8. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
9. Duvoux 2006 Duvoux C, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al.Multicenter randomized trial of HCV treatment with peginterferon-alpha 2a and ribavirin in liver transplant patients with established recurrent hepatitis C: Interim analysis. Journal of Hepatology 2006;44(Suppl 2):S3.
10. Eason 2001 Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplantation 2001;7(8):693-7.
11. Egger 1997 Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
12. Gane 1998 Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al.A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27(5):1403-7.
13. Gluud 2006 Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER.
14. Gurusamy 2007 Gurusamy KS, Samraj K, Davidson BR. Antiviral prophylactic intervention for hepatitis C virus in patients undergoing liver transplantation. (Protocol) Cochrane Database of Systematic Reviews 2007:Issue 3. Art. No.: CD006573. DOI:10.1002/14651858.CD006573.
15. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
16. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006.
17. ICH-GCP 1997 International Conference on Harmonisation of Technical Requiements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1997.
18. Jain 2002 Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transplantation 2002;8(1):40-6.
19. Kamath 2001 Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al.A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-70.
20. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
21. Koneru 2005 Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, et al.Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transplantation 2005;11(2):196-202.
22. Lim 2006 Lim SG, Wai CT, Da Costa M, Sutedja DS, Lee YM, Lee KH, et al.Referral patterns and waiting times for liver transplantation in Singapore. Singapore Medical Journal 2006;47(7):599-603.
23. Macaskill 2001 Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
24. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
25. Newell 1992 Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
26. NHS UK Transplant NHS UK Transplant - Annual Report 2003-2004. http://www.uktransplant.org.uk/ukt/about_us/annual_report/ archive_annual_reports/ann_report_2003_2004.pdf (accessed 14 February 2007).
27. OPTN/SRTR 2005 The Organ Procurement and Transplant Network/ Scientific Registry of Transplant Recipients 2005 Annual Report. http://www.ustransplant.org/annual_reports/current/905_li.pdf (accessed 14 February 2007).
28. RevMan 2003 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
29. Royle 2003 Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
30. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
31. Shiffman 2006 Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, et al.Liver and intestine transplantation in the United States, 1995-2004. American Journal of Transplantation 2006;6(5 Pt 2):1170-87.
32. Sugo 2003 Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, et al.The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surgery Today 2003;33(6):421-5.
33. Sweeting 2004 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75.